Is Narrative Reformulation During Cognitive Analytic Therapy Helpful?
Efficacy of Narrative Reformulation During Cognitive Analytic Therapy: A Randomized Dismantling Trial
1 other identifier
interventional
95
1 country
1
Brief Summary
Narrative reformulation (NR) is an active ingredient of cognitive analytic therapy (CAT) which is assumed to increase engagement and improve outcomes. This trial sought to test these claims. A randomized and controlled dismantling trial method has been designed to investigate treatments outcomes for depressed patients receiving CAT in an Improving Access to Psychological Therapies service. Participants will be randomized to either treatment as usual (full-CAT) or CAT minus narrative reformulation (CAT-NR). The primary outcome measure is the Patient Health Questionnaire (PHQ-9), with secondary outcome measures of anxiety, functioning, helpfulness and the alliance. Outcomes will be assessed at screening, every treatment session and at 8-weeks follow-up. The trial will enable as assessment of the utility of NR during CAT. and whether CAT appears suitable for treating depression in Primary Care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_2 depression
Started Jan 2011
Typical duration for phase_2 depression
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2015
CompletedFirst Submitted
Initial submission to the registry
October 20, 2016
CompletedFirst Posted
Study publicly available on registry
November 11, 2016
CompletedNovember 11, 2016
November 1, 2016
3 years
October 20, 2016
November 10, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Change in depression at end of treatment via the Patient Health Questionnaire-9 (PHQ-9)
This measure screens patients in Primary Care for depression. Scores on the PHQ-9 range from 0-27, a score of \>10 on the PHQ9 used as a cut-off point for identifying clinical caseness. The PHQ-9 is widely recognised as a valid and reliable measure of depressive symptoms items mirror DSM criteria for symptoms of depression.
At 16 weeks.
Secondary Outcomes (4)
Change in anxiety at end of treatment via the Generalized Anxiety Disorder-7 (GAD-7)
At 16 weeks
Change in functioning at the end of treatment on the Work and Social Adjustment Scale (WSAS)
At 16 weeks
Change in the therapeutic alliance at the end of treatment on the Working Alliance Inventory-Short (WAI-S)
At 16 weeks
Change in the helpfulness of the therapy via the the Helpful Aspects of Therapy (HAT)
At 16 weeks
Study Arms (2)
Full-CAT
ACTIVE COMPARATORParticipants in this arm receive an intervention of a full 8-session course of cognitive analytic therapy (CAT). This means that they are assessed then then receive a narrative reformulation, that then leads onto a sequential diagrammatic reformulation and then the change methods and completion.
An 8-session CAT without narrative reformulation (CAT-NR)
EXPERIMENTALParticipants in this arm receive an intervention of a full 8-session course of cognitive analytic therapy (as described above), but crucially with the narrative reformulation (NR) aspect removed. All other aspects of treatment remain the same.
Interventions
Cognitive Analytic Therapy (CAT) is a relational, integrative and time-limited psychotherapy. This is a study with two active arms. Therefore in the full CAT arm the participants receive the full therapy, but in the CAT-NR arm participants get CAT with the narrative reformulation aspect removed.
Eligibility Criteria
You may qualify if:
- clinical diagnosis of depression (conducted using DSM-IV criteria)
- participants needed to reach caseness (i.e. score 10-21) on the PHQ-9
You may not qualify if:
- a PHQ-9 score \<10
- not meeting DSM criteria for depression
- significant risk issues
- co-morbid anxiety disorder
- previous in-patient admission
- significant amount of previous contact with mental health services
- visual impairment
- non-English speaking
- history of overdoses/self-injury
- currently abusing substances
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Clinical Psychology Unit, Department of Psychology, Uni of Sheffield
Sheffield, S10 2TN, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Glenys Parry, PhD
Professor of Mental Health
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- IAPT Programme Director and Consultant Clinical Psychologist
Study Record Dates
First Submitted
October 20, 2016
First Posted
November 11, 2016
Study Start
January 1, 2011
Primary Completion
January 1, 2014
Study Completion
January 1, 2015
Last Updated
November 11, 2016
Record last verified: 2016-11